Mereo Biopharma Group PLC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Mereo BioPharma Group PLC reported its 2025 annual results, revealing Setrusumab's Phase 3 trials for Osteogenesis Imperfecta failed primary fracture reduction endpoints, alongside continued operating losses and a Nasdaq minimum bid price non-compliance notice.
NASDAQ
Mereo BioPharma Group PLC files its 10-K for the year ended December 31, 2024, detailing its financial results and progress in developing innovative therapeutics for rare diseases, particularly setrusumab for osteogenesis imperfecta and alvelestat for alpha-1 antitrypsin deficiency.
NASDAQ
Mereo BioPharma Group plc provides a description of its ordinary shares and American Depositary Shares (ADSs) registered under the Securities Exchange Act of 1934.